Charney D S, Woods S W
Clinical Neuroscience Research Unit, Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven.
J Clin Psychiatry. 1989 Nov;50(11):418-23.
The antipanic efficacy of alprazolam and lorazepam was evaluated in 48 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder in a double-blind random assignment study. On the basis of rating scale scores, both drugs demonstrated similar efficacy in reducing panic attacks and phobic behavior compared with placebo baseline. The doses required to achieve response were approximately double those required for the treatment of generalized anxiety. These results suggest that most, if not all, benzodiazepines may be effective antipanic drugs at high doses. The implications of these findings for drug treatments of choice for recurrent panic attacks are discussed.
在一项双盲随机分组研究中,对48名符合《精神疾病诊断与统计手册》第三版(DSM-III)中广场恐怖症伴惊恐发作或惊恐障碍标准的患者评估了阿普唑仑和劳拉西泮的抗惊恐疗效。根据量表评分,与安慰剂基线相比,两种药物在减少惊恐发作和恐惧行为方面显示出相似的疗效。达到疗效所需的剂量约为治疗广泛性焦虑所需剂量的两倍。这些结果表明,大多数(即便不是全部)苯二氮䓬类药物在高剂量时可能是有效的抗惊恐药物。本文讨论了这些发现对复发性惊恐发作首选药物治疗的意义。